Skip to content

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01643993
Enrollment
300
Registered
2012-07-18
Start date
2012-05-31
Completion date
2014-11-30
Last updated
2015-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Control Media Only, Study hCG and Media

Keywords

IVF, embryo

Brief summary

Techniques to improve pregnancy and delivery rates in IVF cycles have focused not only on the embryos transferred, but also the conditions in the uterus at the time of transfer and implantation. Prior studies have shown that embryos secrete human chorionic gonadotropin (hCG) prior to implantation. However, in IVF cycles, the embryos have limited time to secrete hCG before implantation must occur because embryos are placed into the uterus rather than traveling there from the fallopian tubes. Recent studies have shown that the introduction of hCG into the uterus prior to embryo transfer may make the uterus more receptive to implantation. These studies involved day 3 embryos and the investigators are seeking to evaluate the potential benefits of hCG on implantation rates of blastocysts (day 5 or day 6 embryos). The purpose of this study is to determine whether infusion of human chorionic gonadotropin (hCG) into the uterus immediately prior to embryo transfer results in increased implantation rates. The entire IVF cycle, fresh or frozen, will be conducted per routine. All laboratory culture conditions will be per routine. In fresh and frozen IVF cycles, an embryo transfer will be performed per routine. At the time of embryo transfer, participants will be randomly assigned to either the control group or the hCG group. Patients in the hCG group will have a mock embryo transfer with 20µL of transfer media including 500IU of hCG. Patients in the control group will have a mock embryo transfer with 20µL of transfer media. All post-transfer care and pregnancy monitoring will be identical and per routine protocol.

Interventions

OTHERhCG at the Time of Embryo Transfer

hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.

OTHERControl

Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.

Sponsors

Reproductive Medicine Associates of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
Yes

Inclusion criteria

* all patients 43 years old or under undergoing fresh or frozen IVF cycles are eligible to participate

Exclusion criteria

* patients greater than 43 years old * patinets currently participating in any other research studies

Design outcomes

Primary

MeasureTime frameDescription
Sustained implantation rate12 weeksSustained implantation rate is measured as the number of fetal heart beats seen at the time of patient discharge to OB/GYN care (approximately 8 weeks gestation).

Secondary

MeasureTime frameDescription
Ongoing pregnancy rate9 WeeksThe number of pregnancies with at least one fetal heart beat seen at the time of discharge to OB/GYN care per embryo transfer.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026